Drug Therapy
Drugs are approved in the U.S. by the Food and Drug Administration (FDA) for specific purposes to help guide medical practice.
Related Resources
Bevacizumab (Avastin) Use In HHT
Policy Statement – 2020Hereditary hemorrhagic telangiectasia (HHT, also known as OslerWeber-Rendu Syndrome) is a condition that is characterized by focal proliferation of blood vessels (vascular malformations) in multiple organs. Two of the most commonly affected organs in…
MoreBevacizumab for treating HHT patients with severe hepatic involvement or refractory anemia
Scientific Literature – 2020PLoS One. Authors: Carolina Vázquez, María Laura Gonzalez, Augusto Ferraris, Juan Carlos Bandi, and Marcelo Martín Serra. This article is available for public use and does not require purchase. Click to view the full article.
More
The Science Behind the 2019 Scientific Conference (recorded)
Webinar – 2020Philippe Marambaud, PhD and Andy White, MD discuss important advances in HHT research which were presented at the 2019 HHT International Scientific Conference in Puerto Rico. Learn about advancements in drug therapies for bleeding, screening and trea…
More
Future Treatments for Hereditary Hemorrhagic Telangiectasia
Scientific Literature – 2020Orphanet Journal of Rare Diseases. Authors: Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod and Jean-Jacques Feige. This article is available for public use and does not require purchase. Click to view the full article.
MoreSystemic bevacizumab for high-output cardiac failure in HHT: an international survey of HHT centers
Scientific Literature – 2019Orphanet Journal of Rare Diseases. Authors: Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy and Vivek N. Iyer. This article is available for public use and does not require purchase. Click to view the full article.
MoreSystemic bevacizumab for the treatment of chronic bleeding in HHT
Scientific Literature – 2018Journal of Internal Medicine. Authors: Al-Samkari, H., Kritharis, A., Rodriguez-Lopez, J.M., and Kuter, D.J. This article can be purchased directly from the publisher. Click to view the article description and purchase options.
MoreEndoglin Interacts with VEGFR2 to Promote Angiogenesis
Scientific Literature – 2018The FASEB Journal. Authors: Hongyu Tian, Jennifer J. Huang, Christelle Golzio, Xia Gao, Melissa Hector-Greene, Nicholas Katsanis, and Gerard C. Blobe. This article is available for public use and does not require purchase. Click to view the full arti…
MoreEndoglin Interacts with VEGFR2 to Promote Angiogenesis
Scientific Literature – 2018Angiogenesis is the physiologic process by which new blood vessels arise from pre-existing vessels. Endoglin, a TGF-β coreceptor predominantly expressed in endothelial cells, plays an important role in vascular development and tumor-associated angiog…
MoreHHT: Diagnosis and Management from the Hematologist’s Perspective
Scientific Literature – 2018Haematologica. Authors: Athena Kritharis, Hanny Al-Samkari, and David J Kuter. This article is available for public use and does not require purchase. Click to view the full article.
MoreThe Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia Related Bleeding
Scientific Literature – 2018Mayo Clinic. Author: James R. Gossage, MD This article is available for public use and does not require purchase. Click to view the full article.
More
HHT Scientific Conference Summaries (recorded)
Webinar – 2018Drs. Hughes, Faughnan and Andrejecsk provide a first hand synopsis of the HHT science presented in Dubrovnik, Croatia where over 200 voices were heard from 23 countries. They reviewed the 12th HHT International Conference Executive Summary of…
MoreAbstracts – 12th HHT International Scientific Conference (2017)
Scientific Literature – 2017Angiogenesis. This article can be purchased directly from the publisher. Click to view the article description and purchase options.
MoreExecutive Summary – 12th HHT International Scientific Conference (2017)
Scientific Literature – 2017Angiogenesis. Authors: Jillian W. Andrejecsk, Anna E. Hosman, Luisa M. Botella, Claire L. Shovlin, Helen M. Arthur, Sophie Dupuis-Girod, Elisabetta Buscarini, Christopher C. W. Hughes, Franck Lebrin, Christine L. Mummery, Marco C. Post, and Johannes…
More
Hazardous Natural Health Products in HHT
Article – 2017HHT patients can bleed easily, which is why products that may thin your blood or reduce your ability to clot can be very dangerous. This handout was developed by Daniel Cortes, Pharmacist at the St. Michael’s Hospital HHT Center in Toronto, Canada, t…
MoreEffect of Bevacizumab Nasal Spray on Epistaxis Duration in HHT. A Randomized Clinical Trial
Scientific Literature – 2016JAMA. Authors: Sophie Dupuis-Girod, PhD, Alexis Ambrun, MD, and Evelyne Decullier, PhD. This article is available for public use and does not require purchase. Click to view the full article.
MoreRelated News
Recorded WEBINAR: The Science Behind the 2019 Scientific Conference
Now available!
HHT Scientific Advancement Through Federal Grants
December 10, 2019
Everyone Should Use Backpack Health!
September 4, 2019
2019 Scientific Conference Recap
August 26, 2019